Lipocine Inc (LPCN)

$8.91 +1.19 (15.41%)
Market Cap 45.41M
Revenue (ttm) 11.20M
Net Income (ttm) 10,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.09%
Debt to Equity Ratio 0.00
Volume 110,977
Avg Vol 137,244
Day's Range N/A - N/A
Shares Out 5.55M
Stochastic %K 3%
Beta 0.99
Analysts Sell
Price Target $10.88

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
amazingcrwns
amazingcrwns Feb. 6 at 12:44 PM
$LPCN $BIIB Q4 earnings report is out. "ZURZUVAE fourth quarter revenue of approximately$66.X million showed strong continued demand growth." Congrats to Biogen and Supernus for their continued growth in this market, its nice to see. Increasing revenue numbers can only help Lipocine with Supernus and Biogen doing the heavy lifting in gaining exposure while Lipocine completes their phase 3 trial. Lets hope topline results show the shorter treatment duration (48 hours vs 14 days), faster onset (hours vs days), impoved remission rate (up to 75%) and strong safety claims we've seen in the trial updates all prove to be true. I can't believe Lipocine's entire market cap is still less than 1 quarter of Zurzuvae's revenue, that seems absurd to me at this point. https://investors.biogen.com/node/30141/html
0 · Reply
Ma_pooperz
Ma_pooperz Feb. 5 at 10:22 PM
$LPCN Lmao everything in market burning like dumpster fire and we holding support strong
0 · Reply
DivvyDoo
DivvyDoo Feb. 5 at 9:44 PM
$LPCN https://talvann.substack.com/p/a-new-standard-of-care-in-post-partum
0 · Reply
veseli
veseli Feb. 5 at 9:04 PM
$LPCN Ehh seems those thieves from JP morgan took whole market down by stealing 50 billion by manipulating silver and then paying 920 million fine ... Like bros stole GP of small country and no one ended in prison nor they returned money. And now everyone else is drawn into shit they made because pople need to sell stocks and other securities to cover money those guys tole from them .... Making whole market tank . I tjink it's safe to say we need to buy some guns and go head hunting from judges to JP morgan exacutives , employees and so forth ...
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 8:14 PM
$LPCN zuzurvae and brexanolone are both rapid acting neuroactive steroids (NAS). Both drugs work as modulators of GABA . The real MOA between the 2 drugs is very small. Listen, big pharma is not interested in this
1 · Reply
veseli
veseli Feb. 5 at 5:23 PM
$LPCN It looks like triple bottom on the weekly scale 8.03 , 8.03 , 8.01 maybe time for reversal 🤷
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 4:06 PM
$LPCN again, this really seems seems like a slightly different version of of zurzuvae with the same drug and MOA with slightly different delivery method. Big pharma typically is not interested in this type of drug, so LPCN will likely have to dilute bigly to go it alone.
2 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 2:29 AM
$LPCN how is this any better than zurzuvae? It’s basically slightly better on side effects but not enough to really challenge Biogen. A BP would have to step up fund the fight but the drug isn’t superior enough to zurzuvae to make it worth it
4 · Reply
Ma_pooperz
Ma_pooperz Feb. 3 at 9:38 PM
$LPCN If you ask any woman/mom about childbirth you will almost always hear concern or experience with post partum depression, it affects 5%-50% of pregnancies. Currently zero accessible treatments in terms of time and money.
0 · Reply
az2001
az2001 Feb. 3 at 7:48 PM
$LPCN Took this opportunity to load up some more before upcoming catalysts
2 · Reply
Latest News on LPCN
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 17 days ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 25 days ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 7 weeks ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 2 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 3 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 3 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 4 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 5 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 9 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 9 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 6, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Jan 18, 2024, 8:00 AM EST - 2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine to Present at Biotech Showcase 2024

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

amazingcrwns
amazingcrwns Feb. 6 at 12:44 PM
$LPCN $BIIB Q4 earnings report is out. "ZURZUVAE fourth quarter revenue of approximately$66.X million showed strong continued demand growth." Congrats to Biogen and Supernus for their continued growth in this market, its nice to see. Increasing revenue numbers can only help Lipocine with Supernus and Biogen doing the heavy lifting in gaining exposure while Lipocine completes their phase 3 trial. Lets hope topline results show the shorter treatment duration (48 hours vs 14 days), faster onset (hours vs days), impoved remission rate (up to 75%) and strong safety claims we've seen in the trial updates all prove to be true. I can't believe Lipocine's entire market cap is still less than 1 quarter of Zurzuvae's revenue, that seems absurd to me at this point. https://investors.biogen.com/node/30141/html
0 · Reply
Ma_pooperz
Ma_pooperz Feb. 5 at 10:22 PM
$LPCN Lmao everything in market burning like dumpster fire and we holding support strong
0 · Reply
DivvyDoo
DivvyDoo Feb. 5 at 9:44 PM
$LPCN https://talvann.substack.com/p/a-new-standard-of-care-in-post-partum
0 · Reply
veseli
veseli Feb. 5 at 9:04 PM
$LPCN Ehh seems those thieves from JP morgan took whole market down by stealing 50 billion by manipulating silver and then paying 920 million fine ... Like bros stole GP of small country and no one ended in prison nor they returned money. And now everyone else is drawn into shit they made because pople need to sell stocks and other securities to cover money those guys tole from them .... Making whole market tank . I tjink it's safe to say we need to buy some guns and go head hunting from judges to JP morgan exacutives , employees and so forth ...
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 8:14 PM
$LPCN zuzurvae and brexanolone are both rapid acting neuroactive steroids (NAS). Both drugs work as modulators of GABA . The real MOA between the 2 drugs is very small. Listen, big pharma is not interested in this
1 · Reply
veseli
veseli Feb. 5 at 5:23 PM
$LPCN It looks like triple bottom on the weekly scale 8.03 , 8.03 , 8.01 maybe time for reversal 🤷
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 4:06 PM
$LPCN again, this really seems seems like a slightly different version of of zurzuvae with the same drug and MOA with slightly different delivery method. Big pharma typically is not interested in this type of drug, so LPCN will likely have to dilute bigly to go it alone.
2 · Reply
Aawilliam2003
Aawilliam2003 Feb. 5 at 2:29 AM
$LPCN how is this any better than zurzuvae? It’s basically slightly better on side effects but not enough to really challenge Biogen. A BP would have to step up fund the fight but the drug isn’t superior enough to zurzuvae to make it worth it
4 · Reply
Ma_pooperz
Ma_pooperz Feb. 3 at 9:38 PM
$LPCN If you ask any woman/mom about childbirth you will almost always hear concern or experience with post partum depression, it affects 5%-50% of pregnancies. Currently zero accessible treatments in terms of time and money.
0 · Reply
az2001
az2001 Feb. 3 at 7:48 PM
$LPCN Took this opportunity to load up some more before upcoming catalysts
2 · Reply
JackLewisLPCN
JackLewisLPCN Feb. 3 at 6:44 PM
$LPCN I would officially be surprised if it dropped too far under $8. There isn't enough room between now and April and there should be a run to results, right? Feels like it would be kinda crazy for shares to not be snapped up at $8. Like, conservatively it should be near $12 around results, right?
3 · Reply
dbatech99
dbatech99 Feb. 2 at 11:21 PM
$LPCN islands in the stream chart? 🤮
0 · Reply
steven1x
steven1x Feb. 2 at 8:04 PM
$LPCN fyi https://x.com/persimmonti/status/2018120343425081443?s=61
0 · Reply
ITF
ITF Feb. 2 at 4:50 PM
$LPCN LPCN becoming a hedge against the market. lol
0 · Reply
Ma_pooperz
Ma_pooperz Jan. 29 at 7:07 PM
$LPCN Nothing about this stock's upcoming catalysts have changed. We are getting closer to April mark it.
0 · Reply
NothnSpecial
NothnSpecial Jan. 29 at 4:30 PM
$LPCN wish I could buy some call options here
0 · Reply
dbatech99
dbatech99 Jan. 28 at 6:17 PM
$LPCN eh. This is not the answer I'm looking for.
0 · Reply
amazingcrwns
amazingcrwns Jan. 28 at 4:22 PM
$LPCN Bought the dip, just a small swing position.
0 · Reply
Roy111
Roy111 Jan. 28 at 4:07 PM
$LPCN
0 · Reply
amazingcrwns
amazingcrwns Jan. 28 at 3:29 PM
$LPCN
1 · Reply
Ma_pooperz
Ma_pooperz Jan. 27 at 7:05 PM
$LPCN Volume slowing down, scalpers and scaredy cats leaving, buyers holding and waiting.
1 · Reply
agarfield
agarfield Jan. 27 at 4:42 PM
$LPCN I wish you all the best Patel, 20 years going at this and most potential for the company thus far, seems like we are getting to a finale of sorts. Hopefully he gets his cake and the rest of us get to share some slices.
0 · Reply